Clinical Studies of Histone Deacetylase Inhibitors

H. Miles Prince(Peter MacCallum Cancer Centre), Simon J. Harrison(Peter MacCallum Cancer Centre), Mark Bishton(Nottingham University Hospitals NHS Trust)
Clinical Cancer Research
June 15, 2009
10.1158/1078-0432.ccr-08-2785
Cited by 356

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
|The Lancet|2019|635
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
|Leukemia|2009|586
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580